- BriaCell Therapeutics (BCT) has entered into definitive securities purchase agreements for gross proceeds of US$27.2 million
- BriaCell will issue 5,170,343 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock
- Units are priced at US$5.26. The warrants have a five-and-a-half-year term and an exercise price of US$6.19 per share
- The placement is expected to close on June 7
- BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer
- BriaCell Therapeutics (BCT) is up 4.45 per cent, trading at C$7.74 per share at 11:45 am ET
BriaCell Therapeutics (BCT) has entered into definitive securities purchase agreements for gross proceeds of US$27.2 million.
BriaCell will issue 5,170,343 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock.
Units are priced at US$5.26. The warrants have a five-and-a-half-year term and an exercise price of US$6.19 per share.
This private placement is expected to close on June 7, 2021.
BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer.
BriaCell Therapeutics (BCT) is up 4.45 per cent, trading at C$7.74 per share at 11:45 am ET.
